News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Advertisement

Martina Porter, MD

Advertisement

Articles by Martina Porter, MD

3 Things You Should Know About HS Pathology and Management

ByPER Editorial Staff,Raj Chovatiya, MD, PhD, MSCI,Jason E. Hawkes, MD, MS,Martina Porter, MD
May 1st 2024

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Advertisement

Latest Updated Articles

  • 3 Things You Should Know About HS Pathology and Management
    3 Things You Should Know About HS Pathology and Management

    Published: May 1st 2024 | Updated:



Advertisement
Advertisement

Trending on Dermatology Times

1

Q&A: How Clinicians Are Healing “Overdosed” Skin Damaged by Viral Trends

2

AEON's ABP-450 Achieves Critical Analytical Milestone, Demonstrating High Biosimilarity to BOTOX

3

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

4

Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline

5

Immune Signatures Outperform Clinical Appearance in Treatment Guidance

  • About
  • Advertise
  • Contact Us
  • Job Board
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy Policy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us